logomg.png
Open Demat Account
Open Demat Account

  • SENSEX

    {{sensexData[0].price}} (+{{sensexData[0].change}}%)

  • SENSEX

    {{sensexData[0].price}} ({{sensexData[0].change}}%)

  • NIFTY 50

    {{niftyData[0].open_price}} (+{{niftyData[0].change}}%)

  • NIFTY 50

    {{niftyData[0].open_price}} ({{niftyData[0].change}}%)

  • {{mcxData[2].symbol}}

    {{mcxData[2].price}} (+{{mcxData[2].PerChange}}%)

  • {{mcxData[2].symbol}}

    {{mcxData[2].price}} ({{mcxData[2].PerChange}}%)

  • {{mcxData[0].symbol}}

    {{mcxData[0].price}} (+{{mcxData[0].PerChange}}%)

  • {{mcxData[0].symbol}}

    {{mcxData[0].price}} ({{mcxData[0].PerChange}}%)

  • {{mcxData[1].symbol}}

    {{mcxData[1].price}} (+{{mcxData[1].PerChange}}%)

  • {{mcxData[1].symbol}}

    {{mcxData[1].price}} ({{mcxData[1].PerChange}}%)

  • {{mcxData[3].symbol}}

    {{mcxData[3].price}} (+{{mcxData[3].PerChange}}%)

  • {{mcxData[3].symbol}}

    {{mcxData[3].price}} ({{mcxData[3].PerChange}}%)

Back
Glenmark Life drops after Q4 PAT slides 33% YoY to ₹ 98 cr; Generic API biz down 8% YoY 
(15:41, 25 Apr 2024)
Revenue from operations fell 13.64% YoY to ₹ 536.59 crore in Q4 FY24.

Profit before tax declined 34.39% to ₹ 129.67 crore in the quarter ended 31 March 2024 as compared with ₹ 197.63 crore in the quarter ended 31 March 2023.

EBITDA stood at ₹ 144.6 crore in Q4 FY24, registering the de-growth of 30.91% as compared with ₹ 209.3 crore posted in corresponding quarter last year. In Q4 FY24, EBITDA margin reduced to 26.9% as against 33.7% in Q4 FY23.

During the quarter, Generic API Business fell 8.6% YoY to ₹ 484.6 crore was impacted due to the Red Sea Crisis in external business and de-growth in GPL?s business.

CDMO business declined 37.7% to ₹ 35.4 crore in Q4 FY24 as compared with ₹ 56.8 crore in Q4 FY23.

Revenue from GPL business in Q4 FY24 dropped by 27.8% to ₹ 166.7 crore as compared with ₹ 230.9 crore in Q4 FY23. GPL business contributes 31% of the total revenue from operations. External business saw de-growth of 5.2% YoY on account of delay of shipments due to Red Sea crisis.

Regulated market witnessed 83% growth was driven by YoY growth in Europe and LATAM.

On Financial year 2024 basis, the company reported net profit marginally higher to ₹ 470.9 crore in FY24 as compared with ₹ 467 crore in FY23. Revenue from operations increased 5.6% YoY to ₹ 2,283.2 crore in FY24.

During FY24, company generated strong free cash flow of ₹ 284.5 crore leading to cash and cash equivalents of ₹ 301.4 crore as of 31 March 2024.

Yasir Rawjee, MD & CEO, Glenmark Life Sciences, said, ?FY24 was a milestone year for Glenmark Life Sciences, marked by the successful acquisition by Nirma. With Nirma's commitment and strategic vision, we are poised for accelerated growth and market positioning. We concluded the financial year on a positive note with revenue growth of 5.6% on full year basis, driven by regulated markets in external business. Our commitment to high-quality, innovative solutions and scalability will fuel sustainable long-term growth. These, coupled with a strong order book and demand visibility will ensure steady growth in FY25 and beyond.?

Tushar Mistry, CFO, Glenmark Life Sciences, said, ?Despite global uncertainties and our integration efforts with Nirma, we achieved a revenue growth of 5.6% in FY24. Our annualized margins continue to be in the range of around 30% despite one-time costs such as bonuses and transaction expenses. Our strong free cash flow generation in FY24 has bolstered our financial standing, enabling continued growth while maintaining a debt-free balance sheet.?

In Q4FY24, 6 new products were added to the development grid, of which 4 products are High potent API (HP API) / Oncology class of drugs and 2 are synthetic small molecules. According to IQVIA MAT December 2023, the HP API portfolio now extends to 17 products with an addressable market of $37 billion. 3 products are validated, and 4 products are in advanced stage of development.

Glenmark Life Sciences, a subsidiary of Glenmark Pharmaceuticals, is a developer and manufacturer of select high-value, non-commoditised active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease, central nervous system disease, pain management, and diabetes.

Powered by Capital Market - Live News

No Details of this news available

Mandatory Dematerialization for Transfer of Securities, w.e.f 5th December 2018. Refer to SEBI notification number SEBI/LAD-NRO/GN/2018/24 dated June 08,2018.

Update/Link your Aadhaar Number with your Demat Account by Submitting a photocopy of Aadhaar card along with a request letter/Modification form.

Prevent Unauthorised transactions in your account. Update your mobile numbers/email IDs with your stock brokers.

KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorize your bank to make payment in case of allotment.

Prevent Unauthorized Transactions in your demat account. Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day....... Issued in the interest of investors.

Prevent unauthorized transactions in your trading account ->Update your mobile numbers/email IDs with your stock brokers. Receive information/alerts of your transactions directly from Exchange on your mobile/email at the end of the day.... Issued in the interest of investors.

Filing Complaints on SCORES - Easy & quick.
a. Register on SCORES portal,
b. Provide mandatory details for filing complaints on SCORES like name, PAN, address, mobile number, email ID.
c. Benefits:
   i. Effective communication
   ii. Speedy redressal of the grievances

Investor Awareness regarding the revised guidelines on margin collection

 

Dear Investor,

As you are aware, under the rapidly evolving dynamics of financial markets, it is crucial for investors to remain updated and well-informed about various aspects of investing in securities market. In this connection, please find a link to the BSE Investor Protection Fund website where you will find some useful educative material in the form of text and videos, so as to become an informed investor.

https://www.bseipf.com/investors_education.html

We believe that an educated investor is a protected investor !!!

 

Risk Disclosure on Derivatives

  • out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:
SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

MAGNUM EQUITY BROKING LTD.

SEBI Registration No.: INZ000172031 NSE Member ID: 06529 | BSE Clearing No.:126 | CDSL SEBI Registration No. IN-DP-CDSL-201-2003
DP ID: 12029700 | CIN: U67120MH1996PLC103441

Investor Grievances: grievances@magnum.co.in

Copyright © 2018-2019 Magnum Equity Broking Ltd. All rights reserved

Designed, Developed & Powered by CMOTS Infotech (ISO 9001:2015 Certified)